These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 21422924)

  • 21. [Control of phosphorus and treatment with vitamin D in chronic kidney disease prior to the start of dialysis].
    Sánchez González MC; Fernandez Giraldez E; Valdivielso Revilla JM
    Nefrologia; 2008; 28 Suppl 5():39-45. PubMed ID: 18847419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical epidemiology of cardiovascular disease in chronic kidney disease.
    Kundhal K; Lok CE
    Nephron Clin Pract; 2005; 101(2):c47-52. PubMed ID: 15942250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease.
    Goodman WG
    Semin Dial; 2004; 17(3):209-16. PubMed ID: 15144547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular risk and mineral bone disorder in patients with chronic kidney disease.
    Staude H; Jeske S; Schmitz K; Warncke G; Fischer DC
    Kidney Blood Press Res; 2013; 37(1):68-83. PubMed ID: 23548827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular calcification in nondialyzed patients with chronic kidney disease.
    Qunibi WY
    Semin Dial; 2007; 20(2):134-8. PubMed ID: 17374087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of vascular calcification in CKD patients.
    Massry SG; Smogorzewski M
    Semin Nephrol; 2006 Jan; 26(1):38-41. PubMed ID: 16412824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic kidney disease--mineral and bone disorder: a complex scenario.
    Mejía N; Roman-García P; Miar AB; Tavira B; Cannata-Andía JB
    Nefrologia; 2011; 31(5):514-9. PubMed ID: 21959717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pathogenesis and treatment of vascular calcification in CKD].
    Brancaccio D; Gallieni M; Pasho S; Fallabrino G; Olivi L; Volpi E; Ciceri P; Missaglia E; Ronga C; Brambilla C; Butti A; Rocca-Rey L; Chiarelli G; Cozzolino M
    G Ital Nefrol; 2009; 26 Suppl 45():S20-7. PubMed ID: 19382090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk.
    Toussaint ND; Pedagogos E; Tan SJ; Badve SV; Hawley CM; Perkovic V; Elder GJ
    Nephrology (Carlton); 2012 Jul; 17(5):433-44. PubMed ID: 22574672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new role for vitamin D receptor activation in chronic kidney disease.
    Valdivielso JM; Cannata-Andía J; Coll B; Fernández E
    Am J Physiol Renal Physiol; 2009 Dec; 297(6):F1502-9. PubMed ID: 19625376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality].
    Koizumi M; Fukagawa M
    Clin Calcium; 2010 Nov; 20(11):1700-8. PubMed ID: 21037391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term control of parathyroid hormone and calcium-phosphate metabolism after parathyroidectomy in children with chronic kidney disease.
    Schaefer B; Schlosser K; Wühl E; Schall P; Klaus G; Schaefer F; Schmitt CP
    Nephrol Dial Transplant; 2010 Aug; 25(8):2590-5. PubMed ID: 20181803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vascular calcification in patients with chronic kidney disease: types, clinical impact and pathogenesis.
    Román-García P; Rodríguez-García M; Cabezas-Rodríguez I; López-Ongil S; Díaz-López B; Cannata-Andía JB
    Med Princ Pract; 2011; 20(3):203-12. PubMed ID: 21454988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vascular calcification in chronic kidney disease.
    Covic A; Kanbay M; Voroneanu L; Turgut F; Serban DN; Serban IL; Goldsmith DJ
    Clin Sci (Lond); 2010 Apr; 119(3):111-21. PubMed ID: 20443781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.
    Craver L; Marco MP; Martínez I; Rue M; Borràs M; Martín ML; Sarró F; Valdivielso JM; Fernández E
    Nephrol Dial Transplant; 2007 Apr; 22(4):1171-6. PubMed ID: 17205962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vascular calcification and arterial stiffness in chronic kidney disease: implications and management.
    Toussaint ND; Kerr PG
    Nephrology (Carlton); 2007 Oct; 12(5):500-9. PubMed ID: 17803475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Kidney and bone update : the 5-year history and future of CKD-MBD. Bisphosphonates treatment for chronic kidney disease-mineral and bone disorder].
    Mori H; Okada Y; Tanaka Y; Hashimoto O
    Clin Calcium; 2012 Jul; 22(7):1034-42. PubMed ID: 22750936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Kidney and bone update : the 5-year history and future of CKD-MBD. Disorders of musculoskeletal system in CKD ; bone fracture and periarticular calcification].
    Yamada S; Taniguchi M
    Clin Calcium; 2012 Jul; 22(7):1000-7. PubMed ID: 22750932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone health in chronic kidney disease-mineral and bone disease.
    Gal-Moscovici A; Sprague SM
    Adv Chronic Kidney Dis; 2007 Jan; 14(1):27-36. PubMed ID: 17200041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.